Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- PMID: 29529307
- DOI: 10.1093/rheumatology/key023
Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Abstract
Objectives: This analysis set out to estimate the risk of opportunistic infection (OI) among patients with RA by biologic class.
Methods: The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis is a prospective observational cohort study established to evaluate safety of biologic therapies. The population included adults commencing biologic therapy for RA. The primary outcome was any serious OI excluding tuberculosis (TB). Event rates were compared across biologic classes using Cox proportional hazards with adjustment for potential confounders identified a priori. Analysis of the incidence of TB was performed separately.
Results: In total, 19 282 patients with 106 347 years of follow-up were studied; 142 non-TB OI were identified at a rate of 134 cases/100 000 patient years (pyrs). The overall incidence of OI was not significantly different between the different drug classes; however, the rate of Pneumocystis infection was significantly higher with rituximab than with anti-TNF therapy (adjusted hazard ratio = 3.2, 95% CI: 1.4, 7.5). The rate of TB fell dramatically over the study period (783 cases/100 000 pyrs in 2002 to 38 cases/100 000 pyrs in 2015). The incidence of TB was significantly lower among rituximab users than anti-TNF users, with 12 cases/100 000 pyrs compared with 65 cases/100 000 pyrs.
Conclusions: The overall rate of OI was not significantly different between drug classes; however, a subtle difference in the pattern of OI was seen between the cohorts. Patient factors such as age, gender and comorbidity were the most important predictors of OI.
Similar articles
-
Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Ann Rheum Dis. 2018 Jun;77(6):905-910. doi: 10.1136/annrheumdis-2017-212825. Epub 2018 Mar 28. Ann Rheum Dis. 2018. PMID: 29592917
-
Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.Rheumatology (Oxford). 2018 Apr 1;57(4):651-655. doi: 10.1093/rheumatology/kex469. Rheumatology (Oxford). 2018. PMID: 29340619
-
Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Arthritis Rheumatol. 2021 Oct;73(10):1800-1809. doi: 10.1002/art.41754. Epub 2021 Aug 17. Arthritis Rheumatol. 2021. PMID: 33844458
-
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.Autoimmun Rev. 2015 Jun;14(6):503-9. doi: 10.1016/j.autrev.2015.01.011. Epub 2015 Jan 21. Autoimmun Rev. 2015. PMID: 25617816 Review.
-
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.Ann Rheum Dis. 2015 Dec;74(12):2107-16. doi: 10.1136/annrheumdis-2015-207841. Epub 2015 Sep 22. Ann Rheum Dis. 2015. PMID: 26395500 Review.
Cited by
-
Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.Arthritis Care Res (Hoboken). 2018 Oct 8;71(8):993-1003. doi: 10.1002/acr.23781. Online ahead of print. Arthritis Care Res (Hoboken). 2018. PMID: 30295434 Free PMC article.
-
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy.Clin Rev Allergy Immunol. 2022 Jun;62(3):413-431. doi: 10.1007/s12016-021-08879-w. Epub 2021 Jul 28. Clin Rev Allergy Immunol. 2022. PMID: 34319562 Review.
-
New bitongling (NBTL) ameliorates rheumatoid arthritis in rats through inhibiting JAK2/STAT3 signaling pathway.Eur J Histochem. 2021 Feb 17;65(1):3202. doi: 10.4081/ejh.2021.3202. Eur J Histochem. 2021. PMID: 33634679 Free PMC article.
-
Impact of Host Genetics and Biological Response Modifiers on Respiratory Tract Infections.Front Immunol. 2019 May 7;10:1013. doi: 10.3389/fimmu.2019.01013. eCollection 2019. Front Immunol. 2019. PMID: 31134083 Free PMC article. Review.
-
Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment.Front Immunol. 2021 Jun 4;12:675735. doi: 10.3389/fimmu.2021.675735. eCollection 2021. Front Immunol. 2021. PMID: 34149711 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical